Cost-Effectiveness Analysis of Mavacamten: Strategic Implications for Market Access
Cardiology · Hypertrophic Cardiomyopathy • Other • Jun 21, 2026
Assessment confidence: 60% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
Executive Thesis
The cost-effectiveness analysis of mavacamten in treating obstructive hypertrophic cardiomyopathy is crucial as it may shape treatment guidelines and reimbursement policies. This could significantly affect market access and competitive positioning for mavacamten within the cardiology landscape. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 10 ranked evidence items (4 high-relevance).
Strategic Assessment
The strongest clinical anchor is Association Between Circulating BDNF Levels and Atrial Cardiomyopathy in Patients Undergoing Ablation for Persistent Atrial Fibrillation (ClinicalTrials.gov), sub-indication match (cardiology). In cardiology, 4 regulatory and 4 competitive items passed relevance filtering for Mavacamten. Positive cost-effectiveness outcomes could enhance mavacamten's market share and revenue potential, while negative assessments may limit its adoption and reimbursement.
Competitive Pressure
The most relevant competitive pressure comes from Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025 (Bristol Myers Squibb) — sub-indication match (cardiology); entity match (mavacamten). Secondary pressure from Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26).
Regulatory Outlook
Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (cardiology). The study's findings could influence regulatory decisions regarding treatment recommendations and reimbursement approvals, impacting compliance and market entry strategies.
Key Risks
- Elevated medium regulatory exposure for Mavacamten could delay market entry or constrain labeling if agency review intensifies.
- Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Mavacamten through agency review timelines and labeling constraints if follow-through weakens.
Key Opportunities
- Positive cost-effectiveness outcomes could enhance mavacamten's market share and revenue potential, while negative assessments may limit its adoption and reimbursement.
- Upside for Mavacamten may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
- Bristol Myers Squibb document relevant to the signal.
- The economic value of mavacamten in HCM treatment strategies to enhance market access.
What Would Change This Assessment
- This becomes more urgent if Monitor responses from health authorities regarding cost-effectiveness assessments and potential reimbursement outcomes.
- Additional medium- or high-relevance evidence would materially upgrade this assessment.
- Timeline shift beyond mid term would change urgency.
- Outcome from Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26) would change the regulatory/clinical read.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (cardiology)
FDA document
View sourceFDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BAXFENDY (ORIG)
FDAmedium relevance
Sponsor/company relevance (AstraZeneca); Regulatory pathway relevance (nda)
FDA document
View source
Association Between Circulating BDNF Levels and Atrial Cardiomyopathy in Patients Undergoing Ablation for Persistent Atrial Fibrillation
ClinicalTrials.govhigh relevance
Sub-indication match (cardiology)
FDA document
View sourceLifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceRetrospective Study of COVID-19 Vaccines in Patients Undergoing Immunotherapy for Cancer.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025
Bristol Myers Squibbhigh relevance
Sub-indication match (cardiology); Entity match (mavacamten)
FDA document
View sourceBristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
Bristol Myers Squibbhigh relevance
Sub-indication match (cardiology); Entity match (mavacamten)
FDA document
View sourceBristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol Myers Squibbmedium relevance
Entity match (mavacamten)
FDA document
View sourceBristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyo
Bristol Myers Squibbmedium relevance
Entity match (mavacamten)
FDA document
View sourceU.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypert
Bristol Myers Squibblow relevance
Entity match (mavacamten)
FDA document
View source
A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from Dutch societal perspective.
PubMedmedium relevance
Entity match (mavacamten)
FDA document
View sourceCost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceNK cell-based immunotherapy.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceCost-effectiveness and budget impact of ezetimibe-atorvastatin single-pill combination versus free combination in Chinese adults with hypercholesterolemia.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceNeoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Related Signals
Related Regulatory Precedents
FDA
FDA AP — BAXFENDY (ORIG)
Application NDA219878. Sponsor: ASTRAZENECA AB. Submission status: AP. Submission type: ORIG. Review priority: PRIORITY. Active ingredients: BAXDROSTAT.
SourceFDA
FDA AP — BAXFENDY (ORIG)
Application NDA219878. Sponsor: ASTRAZENECA AB. Submission status: AP. Submission type: ORIG. Review priority: PRIORITY. Active ingredients: BAXDROSTAT.
SourceFDA
FDA AP — BAXFENDY (ORIG)
Application NDA219878. Sponsor: ASTRAZENECA AB. Submission status: AP. Submission type: ORIG. Review priority: PRIORITY. Active ingredients: BAXDROSTAT.
Source